Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PITRESSIN TANNATE vs DDAVP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
Diabetes insipidus (central),Nocturnal enuresis (off-label),Variceal bleeding (off-label)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A,von Willebrand disease (type I)
0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding.
Metabolized primarily by the liver and kidneys via peptidases, with a half-life of about 10-20 minutes for vasopressin itself; the tannate formulation prolongs absorption.
Not significantly metabolized; primarily renal excretion.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Primarily renal (unchanged drug); >90% eliminated by kidneys.
Negligible (<1%); mainly bound to plasma proteins primarily vasopressin-binding proteins and albumin, but binding is not clinically significant.
50%; binding proteins: predominantly albumin.
Approximately 0.1 L/kg (range 0.08–0.12 L/kg). This low Vd indicates minimal tissue distribution, consistent with its predominant plasma volume confinement and renal clearance.
0.3 L/kg; indicates distribution primarily in extracellular fluid.
Intramuscular oil suspension: nearly 100% but with slow release. Subcutaneous: approximately 10–15% due to hydrolysis at injection site. Oral: negligible (<1%) due to enzymatic degradation.
Intranasal: 10-20%; oral: 0.1-0.5% (sublingual tablets); subcutaneous: 100% (absolute bioavailability).
Not significantly renally excreted; no specific dose adjustment recommended based on GFR.
Not recommended if GFR <50 m L/min; use with caution if GFR 50-90 m L/min. No standard dose adjustment available; risk of water intoxication increases in renal impairment.
No specific guidelines; use with caution in hepatic impairment due to potential fluid imbalance.
No dose adjustment recommended based on Child-Pugh class. Use with caution in severe hepatic impairment due to potential for fluid overload.
0.1-0.3 m L (1-3 units) intramuscularly or subcutaneously, with dose adjusted based on response; monitor urine output and serum sodium.
Central diabetes insipidus: 0.05-0.1 mg orally every 12-24 hours (titrate). Nocturnal enuresis: 0.2-0.4 mg orally at bedtime (age ≥6 years). Hemophilia A/v WD: 0.3 mcg/kg intravenous over 15-30 minutes; intranasal dose: 150 mcg (if ≤50 kg) or 300 mcg (if >50 kg); subcutaneous: 0.3 mcg/kg.
Start at lower end of dosing range (0.5 m L initially) due to increased risk of electrolyte disturbances and comorbid conditions; monitor serum sodium and fluid status closely.
Start at lower end of dosing range (e.g., 0.1 mg orally once daily). Monitor serum sodium and fluid balance closely due to increased risk of hyponatremia and renal impairment.
None.
None
Hyponatremia and water intoxication; cardiac effects including arrhythmias and ischemia; mesenteric ischemia; hypersensitivity reactions; use with caution in patients with coronary artery disease, hypertension, or renal impairment.
Risk of hyponatremia,Fluid intake restriction to avoid water intoxication,Seizures in severe hyponatremia,Cardiovascular disease caution (hypertension, coronary artery disease)
Hypersensitivity to vasopressin or components; anuria; chronic nephritis with nitrogen retention; cardiovascular disease (ischemic heart disease, advanced atherosclerosis, coronary thrombosis).
Hypersensitivity to desmopressin or components,Moderate to severe renal impairment (Cr Cl < 50 m L/min),Type IIB or platelet-type von Willebrand disease,Severe hyponatremia
Avoid excessive fluid intake beyond thirst to prevent water intoxication. Limit alcohol, which can inhibit vasopressin release and reduce drug efficacy. No specific food restrictions.
Avoid excessive water intake while on DDAVP. Do not consume grapefruit or grapefruit juice, as it may affect drug metabolism. Limit caffeine intake due to diuretic effects that could counteract DDAVP. Avoid high-sodium foods that may increase thirst and fluid intake.
PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossification at high doses. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Vasopressin may cause uterine contractions and decrease placental perfusion, potentially leading to fetal hypoxia or distress, particularly in the third trimester.
Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal harm, but avoid in preeclampsia due to antidiuretic effect.
It is unknown whether vasopressin is excreted in human breast milk. Due to its high molecular weight (tannate salt) and poor oral bioavailability, significant absorption by a nursing infant is unlikely. However, caution is advised. No M/P ratio is available.
Excreted in breast milk in low amounts (M/P ratio unknown). No adverse effects reported in infants; consider risk-benefit for maternal indication.
No specific dose adjustments are established for pregnancy. However, because of increased plasma volume and renal clearance during pregnancy, lower serum concentrations may occur. Individualize dosing based on clinical response and avoidance of adverse effects such as hyponatremia and hypertension. Use the lowest effective dose.
Volume expansion and increased renal clearance in pregnancy may require dose adjustment; no standard guidelines. For diabetes insipidus, monitor urine output and serum sodium to titrate dose. Avoid in preeclampsia.
Pitressin Tannate is an aqueous suspension of vasopressin for intramuscular injection used for diabetes insipidus. Must be warmed and shaken vigorously before administration to ensure uniform suspension. Inject deeply IM into a large muscle; do not administer IV or subcutaneously. Onset is within 1-2 hours, duration 24-72 hours. Monitor for signs of water intoxication (headache, confusion, seizures) due to antidiuretic effect. Caution in coronary artery disease, hypertension, and renal impairment. Discontinue if abdominal cramps or nausea occur. Not for use in chronic nephrogenic diabetes insipidus.
DDAVP (desmopressin) is a synthetic analog of vasopressin with selective V2 receptor activity, minimizing vasoconstrictor effects. Administer intranasally for central diabetes insipidus; IV for hemophilia A and von Willebrand disease (type I). Monitor serum sodium closely, especially in elderly and young children, due to risk of hyponatremia and water intoxication. Avoid in patients with habitual psychogenic polydipsia. Can be used for nocturnal enuresis, but restrict fluid intake 1 hour before and 8 hours after dose to prevent hyponatremia.
This medication is given as an injection into a muscle, usually every 1-3 days as prescribed.,Do not inject into a vein or under the skin; only into a muscle (buttock or thigh).,Warm the vial in your hands and shake it well just before use to mix the suspension evenly.,Drink only enough fluid to satisfy thirst; excessive fluid intake can lead to water intoxication.,Report any signs of water intoxication: severe headache, confusion, drowsiness, seizures, or difficulty breathing.,Avoid alcohol, which can interfere with the drug's effect and increase urine output.,Store the vial at room temperature away from light and do not freeze.,Monitor urine output and notify your doctor if it does not decrease or if side effects occur.
Take DDAVP exactly as prescribed; do not increase dose without consulting your doctor.,Limit fluid intake while using DDAVP to avoid severe low sodium levels (hyponatremia).,Monitor for symptoms of hyponatremia: headache, nausea, vomiting, confusion, lethargy, muscle cramps.,For nasal spray, do not blow nose for 30 minutes after administration.,Report any weight gain, persistent headache, or change in urination pattern to your healthcare provider.,Do not drink alcohol, as it may increase the risk of hyponatremia.,Store at room temperature; protect from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PITRESSIN TANNATE vs DDAVP, answered by our medical review team.
PITRESSIN TANNATE is a Antidiuretic Hormone Analog that works by Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.. DDAVP is a Antidiuretic Hormone Analog that works by Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PITRESSIN TANNATE and DDAVP depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PITRESSIN TANNATE is: 0.5-1 m L (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.. The standard adult dose of DDAVP is: Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PITRESSIN TANNATE and DDAVP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PITRESSIN TANNATE is classified as Category C. PITRESSIN TANNATE (vasopressin tannate) is classified as FDA Pregnancy Category C. In animal studies, vasopressin has been associated with decreased fetal weight and delayed ossifi. DDAVP is classified as Category C. Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal har. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.